GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
Details of the presentation are as follows:
Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis
Poster Board Number: 810
Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio
Session: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR
Date and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PT
Location: Room 2022/2024 (West Building, Level 2), Moscone Center
For more information about the 2025 ATS International Conference, please visit the conference website, here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT ('dNKT') agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions. These forward-looking statements are based on the Company's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company's expectations with respect to development and commercialization of the Company's product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company's clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company's beliefs and expectations regarding potential shareholder value and future financial performance, the Company's beliefs and estimates about its cash and available resources and its ability to fund its planned operations through any particular date, the Company's beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company's expected milestones in 2025, and the Company's beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operations, its ability to raise additional funds, which may not be available to the Company on acceptable terms, or at all, and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company's common stock on The Nasdaq Capital Market and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company's product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company's products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company's ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), including the risks and uncertainties described in the 'Risk Factors' section of the Company's most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports. In particular, the data discussed in this release is interim data and additional study and additional favorable results will be needed for development of GRI-0621 to continue; this interim data may not be indicative of later or final data for this trial. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Why Cisco Systems Stock Sank on Thursday
Key Points The networking company published the final quarterly earnings report for its fiscal 2025. These showed decent gains in revenue and profitability, but investors were hoping for more. 10 stocks we like better than Cisco Systems › Cisco Systems (NASDAQ: CSCO) wasn't a particularly popular tech stock on Thursday. Investors sold out of the stock following a quarterly earnings report that some found dissatisfying. This sank the share price by more than 1% on a day when the S&P 500 index basically traded flat. Two slight beats Cisco unveiled its fiscal fourth-quarter and full-year 2025 results just after market close on Wednesday. These revealed that the storied computer networking company managed to boost its revenue by 8% year over year in the former period to $14.67 billion. That was slightly above the consensus analyst estimate of $14.62 billion. Cisco attributed this to growth in overall product orders, which it said was 7% across all its regions. It also flagged artificial intelligence (AI) infrastructure products as growth drivers. In the first half of this calendar year, orders for such products topped $2 billion. This is double -- and then some -- management's target of $1 billion for the period. On the bottom line, non-GAAP (adjusted) net income landed at $4 billion, shaking out to $0.99 per share. That was 12% higher than the result for the fourth quarter of 2024, and it edged past the average pundit projection of $0.98. Unsurprising guidance Cisco also proffered guidance for its current (first) quarter and the entirety of fiscal 2026. It's modeling $59 billion to $60 billion in revenue and adjusted earnings per share of $4.00 to $4.06. This is in line with the consensus analyst expectations of, respectively, $59.5 billion and $4.03. While Cisco's quarterly performance certainly wasn't bad, it seems investors were expecting more convincing beats and higher guidance, particularly given that AI tailwind. Should you buy stock in Cisco Systems right now? Before you buy stock in Cisco Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Cisco Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cisco Systems. The Motley Fool has a disclosure policy. Why Cisco Systems Stock Sank on Thursday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
ARKK Inflows Stay Hot
Top 10 Creations (All ETFs) Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change VOO Vanguard S&P 500 ETF 1,995.41 728,920.58 0.27% QQQ Invesco QQQ Trust Series I 1,595.47 371,425.47 0.43% ARKK ARK Innovation ETF 1,357.94 9,965.93 13.63% IWM iShares Russell 2000 ETF 918.10 62,804.57 1.46% IVV iShares Core S&P 500 ETF 839.66 658,231.78 0.13% XLF Financial Select Sector SPDR Fund 498.29 52,671.61 0.95% CIBR First Trust NASDAQ Cybersecurity ETF 422.48 10,294.68 4.10% SPDW SPDR Portfolio Developed World ex-US ETF 412.47 28,315.77 1.46% ARKW ARK Next Generation Internet ETF 348.83 3,171.93 11.00% DIA SPDR Dow Jones Industrial Average ETF Trust 333.54 39,109.43 0.85%Top 10 Redemptions (All ETFs) Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change SPY SPDR S&P 500 ETF Trust -3,406.62 659,041.84 -0.52% SOXL Direxion Daily Semiconductor Bull 3x Shares -554.66 12,738.90 -4.35% XLE Energy Select Sector SPDR Fund -338.56 25,986.70 -1.30% XLV Health Care Select Sector SPDR Fund -209.92 32,008.47 -0.66% ITB iShares U.S. Home Construction ETF -164.87 2,728.29 -6.04% INDA iShares MSCI India ETF -136.52 9,490.64 -1.44% IBB iShares Biotechnology ETF -127.35 5,442.73 -2.34% USD ProShares Ultra Semiconductors -122.00 1,490.80 -8.18% SUSL iShares ESG MSCI USA Leaders ETF -84.41 889.15 -9.49% SOXX iShares Semiconductor ETF -75.09 14,129.56 -0.53%ETF Daily Flows By Asset Class Net Flows ($, mm) AUM ($, mm) % of AUM Alternatives 17.52 10,620.77 0.16% Asset Allocation 4.66 26,994.57 0.02% Commodities E T Fs 268.94 227,388.18 0.12% Currency 606.85 189,935.59 0.32% International Equity 3,890.07 1,964,687.24 0.20% International Fixed Income 100.08 313,636.48 0.03% Inverse 49.69 14,336.11 0.35% Leveraged -719.30 149,878.39 -0.48% Us Equity 4,784.22 7,440,486.90 0.06% Us Fixed Income 1,724.34 1,745,438.53 0.10% Total: 10,727.07 12,083,402.75 0.09%Disclaimer: All data as of 6 a.m. Eastern time the date the article is published. Data is believed to be accurate; however, transient market data is often subject to subsequent revision and correction by the | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Discover Yourself Named to Inc. 5000 for Second Time
Using the universal language of color, the company helps organizations worldwide build stronger teams, improve communications and accelerate performance EXCELSIOR, Minn., August 16, 2025--(BUSINESS WIRE)--Discover Yourself, the world's largest distributor of the Insights Discovery® personality assessment, has once again been named to the Inc. 5000 list of America's Fastest-Growing Private Companies. This second-time honor places the Minnesota-based training firm alongside some of the country's most innovative and dynamic businesses. The Inc. 5000 list is widely regarded as the hallmark of entrepreneurial success, celebrating innovation, customer impact and sustained revenue growth. Earning a spot on the list twice reflects Discover Yourself's strong performance, and its enduring ability to adapt and deliver value in a rapidly changing workplace environment. Easily the most colorful company on the Inc. 5000 list Founded by internationally recognized speaker, author and trainer Scott Schwefel, Discover Yourself transforms communication and teamwork by teaching the universal language of color. Through the Insights Discovery framework, individuals identify their unique blend of Fiery Red, Sunshine Yellow, Earth Green and Cool Blue energies, unlocking self-awareness and awareness of others. This approach enables participants to reduce misunderstandings, build stronger connections and collaborate more effectively. "Most people who train with us have done other personality assessments but rarely use them. With ours, they start applying it immediately because every conversation, every email and every interaction gets better," says Schwefel. Discover Yourself's programs — ranging from leadership development and sales training to executive coaching and team-building workshops — are trusted by global brands such as Caterpillar, 3M, Whirlpool, Zendesk and Workday. The company is actively expanding its reach with new online learning platforms, scalable virtual workshops and digital resources to make its programs accessible to teams anywhere in the world. Its reach spans all 50 states and more than 30 countries, powered in part by newly launched digital clones that can deliver on-demand training in 170 languages. Schwefel, one of only 60 global faculty certified to train other trainers, has personally taken 4,000 CEOs through Insights Discovery training, and has spoken to more than 2000 groups. His TED Talk has nearly four million views. He is also a popular keynote speaker worldwide. "Being named to the Inc. 5000 is more than an award. It's proof our methods work, and that organizations everywhere are hungry for meaningful change," comments Schwefel. Discover Yourself has grown from a two-person operation to 17 employees, who support a global network of more than 300 Insights Discovery certified facilitators. Clients reporting measurable boosts in collaboration, productivity and leadership capability. Visit Discover Yourself to take a one-minute quiz to discover where you fall in the color model. If you'd never experienced Insights Discovery and would like to learn more, contact Scott@ View source version on Contacts Scott@
